LBL-024 + paclitaxel + carboplatin

LBL-024 + paclitaxel + carboplatin is an experimental **three-agent combination therapy** evaluated primarily for first-line treatment of **advanced extrapulmonary neuroendocrine carcinoma (EP-NEC)**. - **LBL-024** is a bispecific antibody that **blocks PD-L1** (programmed death ligand 1) to counteract tumor cell immune evasion and, at the same time, **localizes 4-1BB (CD137) co-stimulation to the tumor microenvironment**, leading to enhanced T cell activation and antitumor immune response. LBL-024's dual targeting aims to combine immune checkpoint blockade and T cell costimulation for synergistic antitumor effects[1][3][5]. - **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that inhibits cancer cell division. **Carboplatin** is a platinum-containing chemotherapy acting by inducing DNA crosslinks and apoptosis in cancer cells[2][4]. This combination regimen is being investigated in multicenter Phase Ib/II and pivotal trials. In recent studies, the regimen demonstrated a high overall response rate and disease control rate in treatment-naive advanced EP-NEC, with a favorable safety profile consistent with established effects of platinum-based chemotherapy and LBL-024 immunotherapy components[3][5].